CAR-T cells secreting tocilizumab scFvs show superior anti-tumor efficacy in in vivo stress test against lymphoma xenograft. (A) Schematic of the Raji lymphoma xenograft model in non-humanized NSG mice. Generated with BioRender. (B) Kaplan–Meier curve for overall survival (n = 6 in each treatment group). Statistical significance was determined by log-rank (Mantel-Cox) test with the Holm–Sidak correction for multiple comparisons against the CAR-EGFRt group (**P < 0.01). (C) Tumor progression was quantified by bioluminescence imaging. Each trace represents an individual mouse. This study was performed once. (D) CD4 and CD8 expression distributions among T cells engineered to express CAR with and without cytokine modulators showed little variation based on construct identity. Thawed cell stocks were surface stained with anti-CD4 and anti-CD8 antibodies and analyzed by flow cytometry. Donor 246’s Tnm cells were used on two separate occasions to generate CAR-T cells (batch 1 and batch 2). No cryopreserved stocks were available for CAR-Toci cells from batch 2 for this analysis. Data from three independent experiments are shown; each test condition was performed with triplicate samples.